6.
Busink E, Kendzia D, Kircelli F, Boeger S, Petrovic J, Smethurst H
. A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway. Eur J Health Econ. 2022; 24(3):377-392.
PMC: 10060297.
DOI: 10.1007/s10198-022-01478-2.
View
7.
Mehrotra R, Williamson D, Betts C, Greco B, Yu E, El-Badry A
. A Prospective Clinical Study to EvaluAte the AbiliTy of the CloudCath System to Detect Peritonitis During In-Home Peritoneal Dialysis (CATCH). Kidney Int Rep. 2024; 9(4):929-940.
PMC: 11101817.
DOI: 10.1016/j.ekir.2024.01.033.
View
8.
Bonomini M, Pandolfi A, Di Liberato L, Di Silvestre S, Cnops Y, Di Tomo P
. L-carnitine is an osmotic agent suitable for peritoneal dialysis. Kidney Int. 2011; 80(6):645-54.
DOI: 10.1038/ki.2011.117.
View
9.
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I
. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981):1975-82.
DOI: 10.1016/S0140-6736(14)61601-9.
View
10.
Jansen M, Hart A, Korevaar J, Dekker F, Boeschoten E, Krediet R
. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002; 62(3):1046-53.
DOI: 10.1046/j.1523-1755.2002.00505.x.
View
11.
Lambie M, Teece L, Johnson D, Petrie M, Mactier R, Solis-Trapala I
. Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. Nephrol Dial Transplant. 2019; 34(9):1585-1591.
PMC: 6735880.
DOI: 10.1093/ndt/gfz034.
View
12.
Connor A, Lillywhite R, Cooke M
. The carbon footprints of home and in-center maintenance hemodialysis in the United Kingdom. Hemodial Int. 2011; 15(1):39-51.
DOI: 10.1111/j.1542-4758.2010.00523.x.
View
13.
Obi Y, Rhee C, Mathew A, Shah G, Streja E, Brunelli S
. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol. 2016; 27(12):3758-3768.
PMC: 5118484.
DOI: 10.1681/ASN.2015101142.
View
14.
Lambie M, Chess J, Donovan K, Kim Y, Do J, Lee H
. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol. 2013; 24(12):2071-80.
PMC: 3839554.
DOI: 10.1681/ASN.2013030314.
View
15.
Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C
. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006; 83(5):1142-8.
PMC: 2668161.
DOI: 10.1093/ajcn/83.5.1142.
View
16.
Yu Z, Lambie M, Davies S
. Longitudinal study of small solute transport and peritoneal protein clearance in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2013; 9(2):326-34.
PMC: 3913234.
DOI: 10.2215/CJN.04420413.
View
17.
Masola V, Bonomini M, Onisto M, Ferraro P, Arduini A, Gambaro G
. Biological Effects of XyloCore, a Glucose Sparing PD Solution, on Mesothelial Cells: Focus on Mesothelial-Mesenchymal Transition, Inflammation and Angiogenesis. Nutrients. 2021; 13(7).
PMC: 8308380.
DOI: 10.3390/nu13072282.
View
18.
Htay H, Cho Y, Pascoe E, Darssan D, Nadeau-Fredette A, Hawley C
. Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. Clin J Am Soc Nephrol. 2017; 12(7):1090-1099.
PMC: 5498362.
DOI: 10.2215/CJN.12321216.
View
19.
Brown E, Bargman J, Van Biesen W, Chang M, Finkelstein F, Hurst H
. Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis - Position Paper for ISPD: 2017 Update. Perit Dial Int. 2017; 37(4):362-374.
DOI: 10.3747/pdi.2017.00018.
View
20.
Teerawattananon Y, Mugford M, Tangcharoensathien V
. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health. 2007; 10(1):61-72.
DOI: 10.1111/j.1524-4733.2006.00145.x.
View